NAYA Biosciences upgraded to Buy from Hold at Maxim

Maxim analyst Jason McCarthy upgraded NAYA Biosciences (NAYA) to Buy from Hold with a $2 price target The firm is positive on the company’s revenue outlook related to lead asset NY-303 in 2L hepatocellular carcinoma while noting that the bifunctional antibody space has been rapidly evolving as positive data, particularly in solid tumors, and continues to emerge, the analyst tells investors in a research note. NAYA, which has just recently come onto the scene via the INVO Bioscience merger, has gone unnoticed so far, but this narrative could change in 2025 as its programs advance and awareness builds, Maxim adds.